CVX.PA Carvolix

Healthcare Medical Devices Euronext Paris
4.90 EUR
Close of Nov 7, 2026
1.33 7.56
Market cap
EUR 305M
P/E
-
P/B
7.00x
ROE
-128.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CVX.PA undervalued?

Graham number

The Graham number of Carvolix cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Carvolix fundamental analysis

No fundamental analysis for Carvolix yet.

Carvolix stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILO…

Full company profile